Tuesday, October 26, 2010

Immune Design Licenses Technology To MedImmune

Seattle-based Immune design Corp., a developer of immunotherapies and vaccines for infectious diseases and cancer, said today that it has entered into a license and development agreement with MedImmune. Financial details of the licensing deal were not disclosed. Immune Design said the deal covers use and commercialization of its proprietary Glucopyranosyl Lipid Adjuvant, which is used as a component of vaccines.